Description
Panelists Mark A. Socinski, MD; David R. Spigel, MD; Jared Weiss, MD; Mark G. Kris, MD; and Ross Camidge, MD, PhD, discuss the recent FDA accelerated approval of upfront pembrolizumab and chemotherapy for patients with metastatic non–small cell lung cancer and share their thoughts on combined therapy versus monotherapy.
Tags
cancer oncology